What is ALK+ cancer?

ALK+ lung cancer is a type of genetic mutation cancer with no known cause, and no known cure once it has spread to other parts of the body. It is caused by a mutation or fusion of the ALK gene.  ALK+ cancers are found in patients of all ages, although on average these patients tend to be younger.

What do we do?

Our aim is simple: To improve the life expectancy for ALK+ cancer patients.

We will do this by:

• Fundraising, we can help drive more of the most vital research for ALK+ patients by providing grants for projects and clinical trials. 
• Advocating for improvements to treatment and clinical trial availability, with government, pharmaceutical companies, regulatory bodies and other organisations.
• Working with relevant charities, medical professionals, government and regulatory bodies, we will effect change among decision makers using our knowledge and experience of ALK+ cancers.
• Keeping abreast of trials, breakthroughs and technologies internationally in the oncology industry, we will better advocate for patients and help accelerate the introduction of lifesaving ALK+ advances.